NCT04926285 2026-03-16
VEN-OM
University of Illinois at Chicago
Phase 1 Completed
Clinical Trials
11 trialsNCT04666649 2025-10-07
Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)
University of Maryland, Baltimore
Phase 1 Completed
NCT02956382 2025-07-18
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
Georgetown University
Phase 1/2 Completed
NCT04070768 2025-05-04
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113
Big Ten Cancer Research Consortium
Phase 1 Completed
NCT04017546 2024-09-19
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS
Cyclacel Pharmaceuticals, Inc.
Phase 1 Completed
NCT03739554 2024-01-25
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL
Cyclacel Pharmaceuticals, Inc.
Phase 1 Completed
NCT03236857 2023-05-22
A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
AbbVie
Phase 1 Completed
NCT02419560 2022-05-24
Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL
University of Virginia
Phase 1 Completed
NCT03625505 2021-09-14
A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia
AbbVie
Phase 1 Completed
NCT01969695 2019-12-19
An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma
AbbVie
Phase 1 Completed
NCT01969669 2017-11-20
A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199
AbbVie
Phase 1 Completed